Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2023-177989

Published: 2023

Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2023-178017

Published: 2023

Journal Articles

Examination of Disparities in Access to Chimeric Antigen Receptor (CAR) T Cell Therapies in Medicare Patients (Pts) with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Had Failed at Least 2 Prior Lines of Therapy (LOT)

Ashley Saunders, Sushmitha Inguva, Scott J Keating, Viktor Chirikov

Blood (2022) 140 (Supplement 1): 10921–10923.

https://doi.org/10.1182/blood-2022-160313

Published: 2022

Journal Articles

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Parker, Fei Fei Liu, Kristen Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J Keating, Sonja Sorensen, Emily Dorman

Blood (2021) 138 (Supplement 1): 3003.

https://doi.org/10.1182/blood-2021-150755

Published: 2021